ESR1 and neoplasm: In nude mice bearing MCF7-Y537S tumor model, combining SAR439859 with palbociclib led to further growth-inhibitory effects compared with monotherapy alone [22] suggesting that the combination of SAR439859 with palbociclib could bring therapeutic benefit to ERα-positive breast cancer patients.